Information Provided By: 
Fly News Breaks for August 18, 2015
ESPR
Aug 18, 2015 | 08:36 EDT
JPMorgan analyst Jessica Fye believes last night's update from Esperion Therapeutics, which included the FDA not requiring a pre-approval cardiovascular outcomes trial for ETC-1002, removes a key overhang on shares. The initial label will be narrower than previously thought, though, Fye tells investors in a research note. She thinks the good news trumps the bad, however, and keeps an Overweight rating on Esperion.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
